The company is incorporated in the PRC on December 01, 2014 and listed in the Stock Exchange of Hong Kong on August 15, 2025 with Main board. The company business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. As of the Latest Practicable Date, all of the drug and drug candidates have been in-house developed by the company.
Headquarters
Room 409, Building H, Self-Numbered Creative Building, No. 2 Tengfei Second Street
Guangzhou; Guangdong;
Postal Code: 510700
Contact Details: Purchase the Guangzhou Innogen Pharmaceutical Group Co. Ltd. (广州银诺医药集团股份有限公司) report to view the information.
Website: http://www.innogenpharm.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service